Miconazole-like Scaffold is a Promising Lead for <i>Naegleria fowleri</i>-Specific CYP51 Inhibitors

Abstract

High Resolution Image Download MS PowerPoint Slide Developing drugs for brain infection by Naegleria fowleri is an unmet medical need. We used a combination of cheminformatics, target-, and phenotypic-based drug discovery methods to identify inhibitors that target an essential N. fowleri enzyme, sterol 14-demethylase (NfCYP51). A total of 124 compounds preselected in silico were tested against N. fowleri . Nine primary hits with EC 50 ≤ 10 μM were phenotypically identified. Cocrystallization with NfCYP51 focused attention on one primary hit, miconazole-like compound 2a . The S -enantiomer of 2a produced a 1.74 Å cocrystal structure. A set of analogues was then synthesized and evaluated to confirm the superiority of the S -configuration over the R -configuration and the advantage of an ether linkage over an ester linkage. The two compounds, S - 8b and S - 9b, had an improved EC 50 and K D compared to 2a . Importantly, both were readily taken up into the brain. The brain-to-plasma distribution coefficient of S - 9b was 1.02 ± 0.12, suggesting further evaluation as a lead for primary amoebic meningoencephalitis.